Chronic Lymphocytic Leukemia Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Chronic Lymphocytic Leukemia Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Chronic Lymphocytic Leukemia Pipeline Outlook Report
In July 2025, AstraZeneca announced a Phase IV study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally [po], twice daily [bd]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of < 50%.
In July 2025, BeiGene announced a study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.
In July 2025, AbbVie conducted a study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 120 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide.
DelveInsight's Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment.
The leading Chronic Lymphocytic Leukemia Companies such as Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
Promising Chronic Lymphocytic Leukemia Therapies such as Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others.
Discover how the Chronic Lymphocytic Leukemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Lymphocytic Leukemia Clinical Trials and Studies
Chronic Lymphocytic Leukemia Emerging Drugs Profile
Pirtobrutinib: Loxo Oncology
Pirtobrutinib is an investigational, oral, highly-selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor, signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia.
Cirmtuzumab: Oncternal Therapeutics
Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 in conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL.
MS-553: MingSight Pharmaceuticals
MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKCβ, a signaling molecule immediately downstream of BTK and PLCγ2 in the B-cell receptor (BCR) pathway. As PKCβ is downstream of both BTK and PLCγ2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKCβ signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of CLL.
NX-2127: Nurix Therapeutics
NX-2127 is an oral small molecule that combines the activity of a targeted BTK degrader with the cereblon immunomodulatory activity of an IKZF degrader. Cereblon immunomodulatory drugs that induce degradation are IKZF1 and IKZF3. Preclinical data support the activity of NX-2127 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to FDA-approved agents. Studies in non-human primates confirm potent BTK degradation with once-daily oral dosing. NX-2127 is being tested in an ongoing Phase I trial for patients with chronic lymphocytic leukemia who have failed prior treatments.
NX-5948: Nurix Therapeutics
NX-5948 is an oral small molecule degrader of BTK. Preclinical data support the activity of NX-5948 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to leading FDA approved agents. NX-5948 lacks cereblon immunomodulatory activity and has demonstrated the ability to cross the blood-brain barrier in animal models. NX-5948 has also demonstrated activity in animal models of autoimmune disease. The drug is currently being evaluated in the Phase I stage of development for the treatment of chronic lymphocytic leukemia.
The Chronic Lymphocytic Leukemia Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment.
Chronic Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market
Explore groundbreaking therapies and clinical trials in the Chronic Lymphocytic Leukemia Pipeline. Access DelveInsight's detailed report now! @ New Chronic Lymphocytic Leukemia Drugs
Chronic Lymphocytic Leukemia Companies
Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives
Scope of the Chronic Lymphocytic Leukemia Pipeline Report
Coverage- Global
Chronic Lymphocytic Leukemia Companies- Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
Chronic Lymphocytic Leukemia Therapies- Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others.
Chronic Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chronic Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Chronic Lymphocytic Leukemia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Chronic Lymphocytic Leukemia Emerging Drugs and Major Companies
Table of Contents
Introduction
Executive Summary
Chronic lymphocytic leukemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chronic lymphocytic leukemia– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Pirtobrutinib: Loxo Oncology
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Cirmtuzumab: Oncternal Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NX-2127: Nurix Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Chronic lymphocytic leukemia Key Companies
Chronic lymphocytic leukemia Key Products
Chronic lymphocytic leukemia- Unmet Needs
Chronic lymphocytic leukemia- Market Drivers and Barriers
Chronic lymphocytic leukemia- Future Perspectives and Conclusion
Chronic lymphocytic leukemia Analyst Views
Chronic lymphocytic leukemia Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 hours ago
- CTV News
Delta plane wing clips empty aircraft during pushback from gate in Atlanta
The company logo graces the side of a Delta Air Lines jetliner at Denver International Airport in Denver, on June 26, 2019. (AP Photo/David Zalubowski, File) ATLANTA — A Delta Air Lines plane clipped another aircraft while pushing back from the gate Sunday morning in Atlanta, the airline said. The wing of the plane 'reportedly made contact' with an empty aircraft, Delta said in a brief written statement to The Associated Press. The flight was scheduled to travel from Atlanta to Guatemala City, according to FlightAware, a website that tracks flight disruptions. Passengers were transferred to another plane following a delay. On board the commercial aircraft were 192 customers, two pilots and four flight attendants. No injuries were reported, according to Delta, which has its headquarters in Atlanta. Additional information on the incident was not immediately available.
Globe and Mail
9 hours ago
- Globe and Mail
3 Reasons to Buy Carnival Stock Like There's No Tomorrow
Key Points Carnival's revenue continues to reach record levels, with the business benefiting from strong demand for cruise travel. Rising profits have helped the management team reduce the company's debt burden. Even though the stock has rocketed higher, investors will be drawn to the current valuation. 10 stocks we like better than Carnival Corp. › Carnival (NYSE: CCL) continues sailing in the right direction, something its shareholders have become extremely optimistic about. That's not a surprise, given that the cruise line business was decimated by the COVID-19 pandemic. However, the company is on much better footing these days as it serves robust demand from consumers. In the past 12 months, shares have soared 104% (as of Aug. 6), showcasing heightened bullishness. Despite this monster performance, here are three reasons why investors should still consider buying this travel stock like there's no tomorrow. Durable demand Carnival's business has benefited from tremendous momentum. During the fiscal 2025 second quarter (ended May 31), the company reported record revenue of $6.3 billion. This figure was up 9.5% year over year and 164% higher than the same period of fiscal 2022. There's clearly strong demand from travelers. Carnival had a whopping $8.5 billion in customer deposits in Q2, a record. Net yields, a measure of a cruise line's pricing power, came in at a record $200.07, after increasing by 7.2% during the second quarter. This was "driven by close-in strength in ticket prices and continued strong onboard spending," CFO David Bernstein said on the Q2 2025 earnings call. The demand for Carnival has been impressive in the years following the pandemic's disruption. Investors might think that the good times will come to an end soon. While the rapid growth the business has registered won't continue indefinitely, there's still reason to remain optimistic over the long term. The cruise industry faces some favorable tailwinds. For instance, younger travelers are more interested in these vacations. There are also more first-time passengers coming aboard. As it pushes to capture the opportunity ahead, Carnival is investing in building new cruise ships. It just opened a new private destination, called the Celebration Key, in July. What's more, Carnival is upgrading its rewards program, which will launch in 2026. This can boost customer loyalty and drive repeat cruise trips. Financial improvements During the pandemic, Carnival was forced to pause its operations. To survive the revenue hit, management had to take on more debt to fund the business. It's understandable if, at the time, investors were worried that Carnival would never get out of its predicament. With each passing quarter these days, the company is making substantial progress when it comes to its financial situation. During Q2, Carnival's operating income increased 66.8% year over year to $934 million. This was another record. To its credit, the business is starting to benefit from being able to better leverage its costs as revenue rises. Cruise and tour operating expenses were up just 2.3% year over year during the second quarter. With profitability showing major improvements, Carnival has been able to clean up its balance sheet as well. It ended Q2 with $27.3 billion of long-term debt, a balance that has been reduced by 20% in the past three years. The company's credit rating was also upgraded by two major agencies, which is a vote of confidence. Carnival's upside Carnival's stock has been a huge winner. However, the valuation is still compelling for new investors, even though the company is operating at a very high level these days. The price-to-earnings (P/E) ratio of 15.8 is no doubt cheap, representing a 36% discount to the overall S&P 500 index. Should the P/E multiple get closer to the benchmark's level, there is sizable upside for patient investors. Carnival's strong demand, improving financials, and attractive valuation are three reasons to buy the stock like there's no tomorrow. Should you invest $1,000 in Carnival Corp. right now? Before you buy stock in Carnival Corp., consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Carnival Corp. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
10 hours ago
- Globe and Mail
The Great Flattening is a quiet evolution as middle managers decline
This is the weekly Work Life newsletter. If you are interested in more careers-related content, sign up to receive it in your inbox. Have you noticed fewer rungs on the corporate ladder lately? For the last few years, as companies invest more capital into artificial intelligence, Big Tech has been cutting layers of management in what's become known as the 'Great Flattening.' Now, new data from Gusto, which provides payroll and HR solutions, shows small and mid-sized businesses (SMBs) are following suit and it's reshaping the way teams are structured, developed and led. From 2022 to 2024, the number of individual contributors per people manager at SMBs has doubled. Back in 2019, managers typically oversaw about three direct reports. Now, that number is about six. Nich Tremper, senior economist at Gusto, says this isn't simply a result of sweeping layoffs, but rather a quiet evolution. 'What seems to be happening is that as folks move on – older folks retire or others shift to new roles – businesses simply aren't backfilling those managerial positions,' he says. The change is largely driven by cost pressures. 'We've seen the average labour cost increase nearly 20 per cent over the last couple of years,' Mr. Tremper says. 'Small businesses don't have a lot of leeway in their budgets, so they're thinking through how best to maximize the productivity of the folks they have on staff. Part of that has come down to reducing management layers.' But the consequences of a leaner org chart extend beyond budgets. What we lose when we flatten While some businesses may appreciate the savings and agility that come with fewer layers of hierarchy, Mr. Tremper cautions against seeing it as a purely positive shift. 'These middle managers are really important for organizations,' he says. 'You have strategic decisions and guidance coming from the highest level of management, but it's individual managers who are turning those directions into actionable steps.' In other words, fewer managers may mean faster decision-making in the short term, but also the risk of teams lacking mentorship, development and day-to-day leadership. 'Highly productive sectors tend to maintain more managers with smaller teams,' Mr. Tremper says. 'It suggests that first-line managers play a critical role in scaling their expertise, developing their teams and ultimately boosting productivity.' Even in lower-productivity industries, measured by total output per hour worked, Gusto found that businesses with a higher share of managers tend to outperform their peers. Managers are opting out, too Not only are businesses hiring fewer managers but existing ones are leaving. In late 2024, Gusto found that the quit rate among managers was about 10 per cent higher than it was in January 2022, when it was more of an employee-driven labour market. 'Quit rates are often viewed as a sign of labour market confidence,' says Mr. Tremper. 'If managers are leaving, it could mean they believe they can find more meaningful work elsewhere. They might be looking to lead teams at other companies or return to being high-performing individual contributors.' Some may even be taking the opportunity to pivot entirely. 'For folks who are maybe no longer managers, this could be a chance to ask: What path do I really want? Do I want to be an individual expert? Or maybe this is the time to start my own business or consulting practice.' Flattening with intention The Great Flattening may seem like a cost-saving trend but it comes with trade-offs. While it can boost short-term agility, businesses that cut too deeply may sacrifice long-term development and stability. Mr. Tremper says business leaders should think carefully about what they're giving up. 'When I think of the most effective managers I've had, they've cared deeply about my professional development. They created opportunities for me to grow beyond my current skill set,' he says. Small businesses especially, he adds, rely on strong teams and strong teams often rely on great managers. 11 per cent According to new data from book summary app company Headway, while many workers are enjoying a slow summer season, more than one in 10 say their workload has increased. Read more Experts say rebranding yourself is about more than a job title or what you wear. It's important to be authentic about how you're changing personally and professionally and share that story over time. On a more tactical level, you can also get new headshots, work with a coach and spend time connecting intentionally with your current network and new peers in your industry. Read more 'Being punctual is a form of non-verbal communication. By showing up on time, you're non-verbally telling that person you care enough about their time and the task at hand. It's a representation of your work ethic and competency,' says etiquette trainer Mariah Grumet Humbert. This article looks at how punctuality norms have evolved over time and how being chronically late can impact your personal brand at work and in life. Read more Robert Half research reveals that Gen Z and professionals in tech are the most likely to search for a new job in the next six months. For the first time since the staffing firm began tracking worker sentiment, the research shows better benefits and perks rank as the highest motivator for workers exploring new roles. Read more
